Longeveron Inc
NASDAQ:LGVN
Intrinsic Value
Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. [ Read More ]
The intrinsic value of one LGVN stock under the Base Case scenario is 2.2 USD. Compared to the current market price of 1.82 USD, Longeveron Inc is Undervalued by 17%.
Valuation Backtest
Longeveron Inc
Run backtest to discover the historical profit from buying and selling LGVN stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Longeveron Inc
Current Assets | 5.8m |
Cash & Short-Term Investments | 5.4m |
Receivables | 111k |
Other Current Assets | 376k |
Non-Current Assets | 6.2m |
PP&E | 3.8m |
Intangibles | 2.3m |
Other Non-Current Assets | 193k |
Current Liabilities | 3.9m |
Accounts Payable | 638k |
Accrued Liabilities | 2.7m |
Other Current Liabilities | 506k |
Non-Current Liabilities | 1.4m |
Other Non-Current Liabilities | 1.4m |
Earnings Waterfall
Longeveron Inc
Revenue
|
709k
USD
|
Cost of Revenue
|
-488k
USD
|
Gross Profit
|
221k
USD
|
Operating Expenses
|
-21.3m
USD
|
Operating Income
|
-21m
USD
|
Other Expenses
|
-1.2m
USD
|
Net Income
|
-22.2m
USD
|
Free Cash Flow Analysis
Longeveron Inc
What is Free Cash Flow?
LGVN Profitability Score
Profitability Due Diligence
Longeveron Inc's profitability score is 10/100. The higher the profitability score, the more profitable the company is.
Score
Longeveron Inc's profitability score is 10/100. The higher the profitability score, the more profitable the company is.
LGVN Solvency Score
Solvency Due Diligence
Longeveron Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Longeveron Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LGVN Price Targets Summary
Longeveron Inc
Ownership
LGVN Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
LGVN Price
Longeveron Inc
Average Annual Return | -4.49% |
Standard Deviation of Annual Returns | 95.66% |
Max Drawdown | -100% |
Market Capitalization | 4.6m USD |
Shares Outstanding | 2 510 000 |
Percentage of Shares Shorted | 3.01% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Longeveron LLC is a clinical stage biotechnology company that engages in the development of cellular therapies for specific aging-related and life-threatening conditions. The company is headquartered in Miami, Florida and currently employs 18 full-time employees. The company went IPO on 2021-02-12. The firm's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The company is sponsoring phase I and II clinical trials in various indications, such as aging frailty, Alzheimer's disease (AD), metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The company is evaluating Lomecel-B as a therapy for aging frailty and is being designed to reduce inflammation associated with aging frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. The firm has completed two multicenter trials in the United States for aging frailty.
Contact
IPO
Employees
Officers
The intrinsic value of one LGVN stock under the Base Case scenario is 2.2 USD.
Compared to the current market price of 1.82 USD, Longeveron Inc is Undervalued by 17%.